Sökning: onr:"swepub:oai:DiVA.org:uu-415908" >
177Lu-DOTATATE Ther...
177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated With Chemotherapy : Analysis of Outcome, Safety and Their Determinants
-
- Fröss-Baron, Katarzyna (författare)
- Uppsala universitet,Endokrin tumörbiologi
-
- Garske, Ulrike, 1963- (författare)
- Uppsala universitet,Radiologi,Department of Nuclear Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
-
- Welin, Staffan (författare)
- Uppsala universitet,Onkologisk endokrinologi
-
visa fler...
-
- Granberg, Dan (författare)
- Karolinska Institutet,Uppsala universitet,Onkologisk endokrinologi
-
- Eriksson, Barbro (författare)
- Uppsala universitet,Endokrin tumörbiologi
-
- Khan, Tanweera Shaheena (författare)
- Uppsala universitet,Endokrin tumörbiologi
-
- Sandström, Mattias (författare)
- Uppsala universitet,Radiologi
-
- Sundin, Anders, 1954- (författare)
- Uppsala universitet,Radiologi
-
visa färre...
-
(creator_code:org_t)
- 2020-02-25
- 2021
- Engelska.
-
Ingår i: Neuroendocrinology. - : S. Karger. - 0028-3835 .- 1423-0194. ; 111:4, s. 330-343
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://www.karger.c...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objective: To retrospectively analyze toxicity, progression-free survival (PFS), overall survival (OS) and their determinants in patients with advanced pancreatic neuroendocrine tumors (panNETs), previously pretreated with chemotherapy, undergoing peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE.Methods: In total, 102 patients with advanced panNETs, previously pretreated with one (67%) or several (33%) lines of chemotherapy were included, of whom 90 % had progressive disease and the majority (74.5%) with grade 2 tumors. 177Lu-DOTATATE, 7.4 GBq per cycle, was administered with 6 to 8 weeks interval, in 88 % of patients utilizing a dosimetry-guided protocol, until an absorbed dose of 23 Gy to the kidneys was reached.Results: Mean 32±10.9 GBq per patient was administered in 1-10 cycles starting median 36 months after panNET diagnosis. Median follow-up was 34 months. Median PFS was 24 months and median OS was 42 months from start of PRRT. Independent risk factors for both progression and death were liver tumor burden >50%, more than one line of previous chemotherapy and elevated alkaline phosphatase (ALP). Resection of the primary tumor was linked to longer survival. Bone marrow toxicity grade 3-4 occurred in 10.8%. One patient (1.0 %) developed acute myeloid leukemia. Bone marrow toxicity was unrelated to type and length of previous chemotherapy, amount of administered activity and absorbed dose to the bone marrow.Conclusion: 177Lu-DOTATATE therapy was feasible, highly effective and safe in patients with advanced panNETs heavily pretreated with chemotherapy. More than one line of chemotherapy was a therapy related independent risk factor for shorter PFS and OS.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Oncology
- Onkologi
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Fröss-Baron, Kat ...
-
Garske, Ulrike, ...
-
Welin, Staffan
-
Granberg, Dan
-
Eriksson, Barbro
-
Khan, Tanweera S ...
-
visa fler...
-
Sandström, Matti ...
-
Sundin, Anders, ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Neuroendocrinolo ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet